High-density lipoprotein as a therapeutic target: Clinical evidence and treatment strategies

American Journal of Cardiology

Volumn 96, Issue 9 SUPPL. 1, 2005, Pages 50-58

  Toth, Peter P ^a,b  

^a Sterling Rock Falls Clinic ^*  (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; ANTICOAGULANT AGENT; ANTIINFLAMMATORY AGENT; ATORVASTATIN; CYCLOSPORIN; CYTOCHROME P450 INHIBITOR; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MACROLIDE; NICOTINIC ACID; PRAVASTATIN; PYRROLE DERIVATIVE; RIMONABANT; SIMVASTATIN; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLELITHIASIS; CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DYSPEPSIA; FLUSHING; GASTROINTESTINAL DISEASE; HUMAN; HYPERGLYCEMIA; HYPERURICEMIA; LIFESTYLE; LIPID BLOOD LEVEL; LIVER TOXICITY; METABOLIC DISORDER; METABOLIC SYNDROME X; MOLECULAR RECOGNITION; MORBIDITY; MYOPATHY; PREMATURITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 27744576421     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2005.08.008     Document Type: Conference Paper

References (82)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation 106 2002 3143-3421
2. P.P. Toth High-density lipoprotein and cardiovascular disease Circulation 109 2004 1809 1812
3. A.M. Gotto Jr, E.A. Brinton Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease a working group report and update J Am Coll Cardiol 43 2004 717 724
4. W.P. Castelli Cholesterol and lipids in the risk of coronary artery disease - the Framingham Heart Study Can J Cardiol 4 suppl A 1988 5A 10A
5. W.P. Castelli, R.J. Garrison, P.W.F. Wilson, R.D. Abbott, S. Kalousdian, W.B. Kannel Incidence of coronary heart disease and lipoprotein cholesterol levels the Framingham Study JAMA 256 1986 2835 2838
6. U. Goldbourt, J.S. Yaari, J.H. Medalie Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality a 21-year follow-up of 8,000 men Arterioscler Thromb Vasc Biol 17 1997 107 113
7. N.E. Miller, D.S. Thelle, O.H. Førde, O.D. Mjøs The Tromsø Heart-Study. High-density lipoprotein and coronary heart disease: a prospective case-control study Lancet 1 1977 965 968
8. M.J. Stampfer, F.M. Sacks, S. Salvin, W.C. Willett, C.H. Hennekens A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction N Engl J Med 325 1991 373 381
9. I. Shai, E.B. Rimm, S.E. Hankinson, G. Curhan, J.E. Manson, N. Rifai, M.J. Stampfer, J. Ma Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women potential implications for clinical guidelines Circulation 110 2004 2824 2830
10. J. Willeit, S. Kiechl, F. Oberhollenzer, G. Rungger, G. Egger, E. Bonora, M. Mitterer, M. Muggeo Distinct risk profiles of early and advanced atherosclerosis prospective results from the Bruneck Study Arterioscler Thromb Vasc Biol 20 2000 529 537
11. A.W.E. Weverling-Rijnsburger, I.J.A. Jonkers, E. van Exel, J. Gusseklao, R.G. Westendorp High-density vs low-density lipoprotein cholesterol as the risk factor for coronary artery disease and stroke in old age Arch Intern Med 163 2003 1549-1544
12. P. Shah, J. Amin Low high-density lipoprotein level is associated with increased restenosis rate after coronary angioplasty Circulation 85 1992 1279 1285
13. A.P. Burke, A. Farb, G.T. Malcom, Y. Liang, J.E. Smialek, R. Virmani Plaque rupture and sudden death related to exertion in men with coronary artery disease JAMA 281 1999 921 926
14. J. Genest Jr, J.R. McNamara, J.M. Ordovas, J.L. Jenner, S.R. Silberman, K.M. Anderson, P.W. Wilson, D.N. Salem, E.J. Schaefer Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein(a) abnormalities in men with premature coronary artery disease J Am Coll Cardiol 19 1992 792 802
15. H.B. Rubins, S.J. Robins, D. Collins, A. Iranmanesh, T.J. Wilt, D. Mann, M. Mayo-Smith, F.H. Faas, M.B. Elam, G.H. Rutan Distribution of lipids in 8,500 men with coronary artery disease Am J Cardiol 75 1995 1196 1201
16. American Heart Association, American Stroke Association. Heart Disease and Stroke Statistics - 2004 Update. Available at: http://www.americanheart.org/ downloadable/heart/1072969766940HSStats2004Update.pdf. Accessed January 23, 2004.
17. C.T. Sempos, J.I. Cleeman, M.D. Carroll, C.L. Johnson, P.S. Bachorik, D.J. Gordon, V.L. Burt, R.R. Briefel, C.D. Brown, K. Lippel Prevalence of high blood cholesterol among US adults an update based on guidelines from the second report of the National Cholesterol Education Program Adult Treatment Panel JAMA 269 1993 3009 3014
18. L. Mosca, S.M. Grundy, D. Judelson, K. King, M. Limacher, S. Oparil, R. Pasternak, T.A. Pearson, R.F. Redberg, S.C. Smith Jr, M. Winston, S. Zinberg Guide to preventive cardiology for women. AHA/ACC scientific statement: consensus panel statement Circulation 99 1999 2480 2484
19. M.H. Davidson, P.P. Toth Comparative effects of lipid-lowering therapies Prog Cardiovasc Dis 47 2004 73 104
20. E.S. Ford, W.H. Giles, W.H. Dietz Prevalence of the metabolic syndrome among US adults findings from the third National Health and Nutrition Examination Survey JAMA 287 2002 356 359
21. C.J. Girman, T. Rhodes, M. Mercuri, K. Pyörälä, J. Kjekshus, T.R. Pedersen, P.A. Beere, A.M. Gotto, M. Clearfield 4S Group and the AFCAPS/TexCAPS Research Group The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) Am J Cardiol 93 2004 136 141
22. R.C. Turner, H. Millns, H.A.W. Neil, I.M. Stratton, S.E. Manley, D.R. Matthews, R.R. Holman Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23) BMJ 316 1998 823 828
23. L.O. Martinez, S. Jacquet, J.P. Esteve, C. Rolland, E. Cabezon, E. Champagne, T. Pineau, V. Georgeaud, J.E. Walker, F. Terce Ectopic β-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis Nature 421 2003 75 79
24. R.X. Ioka, M.J. Kang, S. Kamiyama, D.M. Kim, K. Magoori, A. Kamataki, Y. Ito, Y.A. Takei, M. Sasaki, T. Suzuki Expression cloning and characterization of a novel glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein, GPI-HBP-I J Biol Chem 278 2003 7344 7349
25. M. Krieger Scavenger receptor class B type I is a multiligand HDL receptor that influences diverse physiologic systems J Clin Invest 108 2001 793 797
26. G. Wallidius, I. Jungner, I. Holme, A.H. Aastveit, W. Kolar, E. Steiner High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study) a prospective study Lancet 358 2001 2026 2033
27. M. Aviram, E. Hardak, J. Vaya, S. Mahmood, S. Milo, A. Hoffman, S. Billicke, D. Draganov, M. Rosenblatt Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions Circulation 101 2000 2510 2517
28. B. Garner, P.K. Witting, A.R. Waldeck, J.K. Christison, M. Raftery, R. Stocker Oxidation of high-density lipoproteins. I J Biol Chem 273 1998 6080 6087
29. 3-mediated inhibition of thrombin-induced platelet aggregation and fibrinogen binding occurs via decreased production of phosphoinositide-derived second messengers 1,2-diacylglycerol and inositol 1,4,5-tris-phosphate Arterioscler Thromb Vasc Biol 18 1998 861 869
30. P.J. Barter Inhibition of endothelial cell adhesion molecule expression by high density lipoproteins Clin Exp Pharmacol Physiol 24 1997 286 287
31. X.-P. Li, S.-P. Zhao, X.Y. Zhang, L. Liu, M. Gao, Q.-C. Zhou Protective effect of high density lipoprotein on endothelium-dependent vasodilatation Int J Cardiol 73 2000 231 236
32. B. Lekvau, S. Hermann, G. Theilmeier, M. van der Giet, J. Chun, O. Schober, M. Schafers High-density lipoprotein stimulates myocardial perfusion in vivo Circulation 110 2004 3355 3359
33. M. Viņals, J. Martínez-González, L. Badimon Regulatory effects of HDL on smooth muscle cell prostacyclin release Arterioscler Thromb Vasc Biol 19 1999 2405 2411
34. J.R. Nofer, B. Levkau, I. Wolinska, R. Junker, M. Fobker, A. von Eckardstein, V. Seedorf, G. Assmann Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids J Biol Chem 276 2001 34480 34485
35. D.J. Gordon, J.L. Probstfield, R.J. Garrison, J.D. Neaton, W.P. Castelli, J.D. Knoke, D.R. Jacobs Jr, S. Bangdiwala, H.A. Tyroler High-density lipoprotein cholesterol and cardiovascular disease four prospective American studies Circulation 79 1989 8 15
36. M.H. Frick, O. Elo, K. Haapa, O.P. Heinonen, P. Heinsalmi, P. Helo, J.K. Huttunen, P. Kaitaniemi, P. Koskinen, V. Manninen Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease N Engl J Med 317 1987 1237 1245
37. V. Manninen, M.O. Elo, M.H. Frick, K. Haapa, O.P. Heinonen, P. Heinsalmi, P. Helo, J.K. Huttunen, P. Kaitaniemi, P. Koskinen Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study JAMA 260 1988 641 651
38. H.B. Rubins, S.J. Robins, D. Collins, C.L. Fye, J.W. Anderson, M.B. Elam, F.H. Faas, E. Linares, E.J. Schaefer, G. Schectman, T.J. Wilt, J. Wittes Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol N Engl J Med 341 1999 410 418
39. S.J. Robins, D. Collins, J.T. Wittes, V. Papademetriou, P.C. Deedwania, E.J. Schaefer, J.R. McNamara, M.L. Kashyap, J.M. Hershman, L.F. Wexler, H.B. Rubins VA-HIT Study Group Veterans Affairs High-Density Lipoprotein Intervention Trial. Relation of gemfibrozil treatment and lipid levels with major coronary events. VA-HIT: a randomized controlled trial JAMA 285 2001 1585 1591
40. BIP Study Group Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease the Bezafibrate Infarction Prevention (BIP) study Circulation 102 2000 21 27
41. The Coronary Drug Project Research Group Clofibrate and niacin in coronary heart disease JAMA 231 1975 360 381
42. P.L. Canner, K.G. Berge, N.K. Wenger, J. Stamler, L. Friedman, R.J. Prineas, W. Friedewald Fifteen year mortality in Coronary Drug Project patients long-term benefit with niacin J Am Coll Cardiol 8 1986 1245 1255
43. B.G. Brown, X.Q. Zhao, A. Chait, L.D. Fisher, M.C. Cheung, J.S. Morse, A.A. Dowdy, E.K. Marino, E.L. Bolson, P. Alaupovic, J. Frohlich, J.J. Albers Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease N Engl J Med 345 2001 1583 1592
44. A.J. Taylor, L.E. Sullenberger, H.J. Lee, J.K. Lee, K.A. Grace Arterial Biology for the Investigation of the Treatment of the Effects of Reducing Cholesterol (ARBITER) 2 a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins [erratum in: Circulation 2004;110:3615] Circulation 110 2004 3512 3517
45. S.E. Nissen, T. Tsunoda, E.M. Tuzcu, P. Schoenhagen, C.J. Cooper, M. Yasin, G.M. Eaton, M.A. Lauer, W.S. Sheldon, C.L. Grines Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes a randomized controlled trial JAMA 290 2003 2292 2300
46. F.M. Sacks The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease expert group recommendations Am J Cardiol 90 2002 139 143
47. L. Mosca, L.J. Appel, E.J. Benjamin, K. Berra, N. Chandra-Strobos, R.P. Fabunmi, D. Grady, C.K. Haan, S.N. Hayes, D.R. Judelson Evidence-based guidelines for cardiovascular disease prevention in women Circulation 109 2004 672 693
48. American Diabetes Association Dyslipidemia management in adults with diabetes Diabetes Care 27 suppl 1 2004 S68 S71
49. H.N. Ginsberg Nonpharmacologic management of low levels of high-density lipoprotein cholesterol Am J Cardiol 86 2000 41L 45L
50. E. Dewailly, C. Blanchet, S. Gingras, S. Lemieux, B.J. Holub Fish consumption and blood lipids in three ethnic groups of Quebec (Canada) Lipids 38 2003 359 365
51. J.R. Downs, M. Clearfield, S. Weis, E. Whitney, D.R. Shapiro, P.A. Beere, A. Langendorfer, E.A. Stein, W. Kruyer, A.M. Gotto Jr Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels results of AFCAPS/TexCAPS JAMA 279 1998 1615 1622
52. J. Shepherd, G.J. Blauw, M.B. Murphy, E.L.E.M. Bollen, B.M. Buckley, S.M. Cobbe, I. Ford, A. Gaw, M. Hyland, J.W. Jukema Pravastatin in elderly individuals at risk of vascular disease (PROSPER) a randomised controlled trial Lancet 360 2002 1623 1630
53. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals a randomised placebo-controlled trial Lancet 360 2002 7 22
54. C.M. Ballantyne, A. Herd, L. Ferlic, D.K. Dunn, J.A. Farmer, P.H. Jones, J.R. Schein, A.M. Gotto Jr Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy Circulation 99 1999 736 743
55. G. Martin, H. Duez, C. Blanquart, V. Berezowski, P. Poulain, J.C. Fruchart, J. Najib-Fruchart, C. Glineur, B. Staels Statin-induced inhibition of the Rho-signaling pathway activates PPAR-α and induces HDL apoA-I J Clin Invest 107 2001 1423 1432
56. P. Jones, S. Kafonek, I. Laurora, D. Hunninghake CURVES Investigators Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study) Am J Cardiol 81 1998 582 587
57. P.H. Jones, M.H. Davidson, E.A. Stein, H.E. Bays, J.M. McKenney, E. Miller, V.A. Cain, J.W. Blasetto STELLAR Study Group Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial) Am J Cardiol 92 2003 152 160
58. J.R. Crouse 3rd, J. Frohlich, L. Ose, M. Mercuri, J.A. Tobert Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I J Am Coll Cardiol 83; 1999 1476 1477
59. D.B. Hunninghaake, E.A. Stein, H.E. Bays, D.J. Rader, R.R. Chitra, S.G. Simonsen, D.W. Schneck Rosuvastatin improves the atherogenic and atheroprotective lipid profiles in patients with hypertriglyceridemia Coron Artery Dis 15 2004 115 123
60. R.C. Pasternak, S.C. Smith Jr, C.N. Bairey-Merz, S.M. Grundy, J.I. Cleeman, C. Lenfant ACC/AHA/NHLBI clinical advisory on the use and safety of statins J Am Coll Cardiol 40 2002 567 572
61. M.H. Davidson, P.P. Toth Comparative effects of lipid-lowering therapies Prog Cardiovasc Dis 47 2004 73 104
62. V.G. Athyros, A.A. Papageorgiou, V.V. Athyrou, D.S. Demitriadis, A.N. Pehlivanidis, A.G. Kontopoulos Atorvastatin versus four statin-fibrate combinations in patients with familial combined hyperlipidaemia J Cardiovasc Risk 9 2002 33 39
63. V.G. Athyros, A.A. Papageorgiou, V.V. Athyrou, D.S. Demitriadis, A.G. Kontopoulos Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia Diabetes Care 25 2002 1198 1202
64. ACCORD trial. Protocol abstract November 14, 2002. Available at: https://www.accordtrial.org/public/frames.cfm. Accessed April 9, 2004.
65. M.H. Davidson Combination therapy for dyslipidemia safety and regulatory considerations Am J Cardiol 90 suppl 2002 50K 60K
66. T. Prueksaritanont, J.J. Zhao, B. Ma, B.A. Roadcap, C. Tang, Y. Qiu, L. Liu, J.H. Lin, P.G. Pearson, T.A. Baillie Mechanistic studies on metabolic interactions between gemfibrozil and statins J Pharmacol Exp Ther 301 2002 1042 1051
67. T. Sakai, V.S. Kamanna, M.L. Kashyap Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol Arterioscler Thromb Vasc Biol 21 2001 1783 1789
68. J. Pan, M. Lin, R. Kesala, J. Van, M. Charles Niacin treatment of the atherogenic lipid profile and Lp(a) in diabetes Diabetes Obes Metab 4 2002 255 261
69. J.A. Pieper Overview of niacin formulations differences in pharmacokinetics, efficacy, and safety Am J Health Syst Pharm 60 suppl 2 2003 S9 S14
70. J.M. McKenney, J.D. Proctor, S. Harris, V.M. Chinchili A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients JAMA 271 1994 672 677
71. R.H. Knopp, J. Ginsberg, J.J. Albers, C. Hoff, J.T. Ogilvie, G.R. Warnick, E. Burrows, B. Retzlaff, M. Poole Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects clues to mechanism of action of niacin Metabolism 34 1985 642 650
72. J.T. Van, J. Pan, T. Wasty, E. Chan, X. Wu, M.A. Charles Comparison of extended-release niacin and atorvastatin monotherapies and combination treatment of the atherogenic lipid profile in diabetes mellitus Am J Cardiol 89 2002 1306 1308
73. R.H. Knopp, P. Alagona, M. Davidson, A.C. Goldberg, S.D. Kafonek, M. Kashyap, D. Sprecher, H.R. Superko, S. Jenkins, S. Marcovina Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia Metabolism 47 1998 1097 1104
74. Physicians' Desk Reference 58th ed 2004 Thomson PDR Montvale, NJ 1792 1797 Advicor (niacin extended-release and lovastatin tablets) [prescribing information]
75. M.L. Kashyap, M.E. McGovern, K. Berra, J.R. Guyton, P.O. Kwiterovich Jr, W.L. Harper, P.D. Toth, L.K. Favrot, B. Kerzner, S.D. Nash, H.E. Bays, P.D. Simmons Long-term safety and efficacy of a once-daily niacin/lovastatin formulation in patients with dyslipidemia Am J Cardiol 89 2002 672 678
76. M.B. Elam, D.B. Hunninghake, K.B. Davis, R. Garg, C. Johnson, D. Egan, J.B. Kostis, D.S. Sheps, E.A. Brinton Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease. The ADMIT study: a randomized trial JAMA 284 2000 1263 1270
77. S.M. Grundy, G.L. Vega, M.E. McGovern, B.R. Tulloch, D.M. Kendall, D. Fitz-Patrick, O.P. Ganda, R.S. Rosenson, J.B. Buse, D.D. Robertson, J.P. Sheehan Diabetes Multicenter Research Group Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes results of the Assessment of Diabetes Control and Evaluation of the Efficacy of Niaspan Trial Arch Intern Med 162 2002 1568 1576
78. P.P. Toth Reverse cholesterol transport high-density lipoprotein's magnificent mile Curr Atheroscler Rep 5 2003 386 393
79. P.P. Toth, M.H. Davidson Therapeutic interventions targeted at the augmentation of reverse cholesterol transport Curr Opin Cardiol 19 2004 374 379
80. G.J. de Grooth, J.A. Kuivenhoven, A.F.H. Stalenhoef, J. de Graaf, A.H. Zwinderman, J.L. Posma, A. Van Tol, J.J. Kastelein Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans a randomized phase II dose-response study Circulation 105 2002 2159 2165
81. B.K. Skrumsager, K.K. Nielsen, M. Müller, G. Pabst, P.G. Drake, B. Edsberg Ragaglitazar the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPARα and γ agonist in healthy subjects and patients with type 2 diabetes J Clin Pharmacol 43 2003 1244 1256
82. C.P. Sparrow, J. Baffic, M.-H. Lam, E.G. Lund, A.D. Adams, X. Fu, N. Hayes, A.B. Jones, K.L. Macnaul, J. Ondeyka A potent synthetic LXR agonist is more effective than cholesterol loading at inducing ABCA1 mRNA and stimulating cholesterol efflux J Biol Chem 277 2002 10021 10027